Randomized Phase II Study of Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) With or Without ImmTher for Newly Diagnosed High Risk Ewing's Sarcoma.

Trial Profile

Randomized Phase II Study of Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) With or Without ImmTher for Newly Diagnosed High Risk Ewing's Sarcoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 May 2016

At a glance

  • Drugs ImmTher (Primary) ; Cyclophosphamide; Dexrazoxane; Doxorubicin; Vincristine
  • Indications Ewing's sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Mar 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 06 May 2015 Planned End Date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
    • 06 May 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top